Open AccessMycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial
Author(s) -
Gershon Frisch,
Julie Lin,
Jordan L. Rosenstock,
Glen S. Markowitz,
Vivette D. D’Agati,
Jai Radhakrishnan,
Dean C. Preddie,
John R. Crew,
Anthony M. Valeri,
Gerald B. Appel
Publication year - 2005
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfh974
Subject(s) - medicine , proteinuria , placebo , nephropathy , renal function , urology , gastroenterology , creatinine , kidney disease , surgery , kidney , diabetes mellitus , endocrinology , pathology , alternative medicine
IgA nephropathy (IgAN) is the most common form of glomerulonephritis worldwide. Up to 40% progress to end-stage renal disease (ESRD) over 10-20 years. Currently, treatment is limited. We studied the use of mycophenolate mofetil (MMF) vs placebo in a group of North American IgAN patients at high risk for progressive disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom